A series of reports released today by MTPConnect, an independent, industry-led organisation, highlight the key role the MedTech sector played in the COVID-19 pandemic response. The reports, welcomed by the Medical Technology Association of Australia (MTAA), reveal how the MedTech, biotechnology and pharmaceutical sector was impacted by COVID-19 at local and multinational levels, as well…

Read More

How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…

Read More

Tracking the incidence of COVID-19 globally, it is understood that people over the age of 60 with a pre-existing chronic condition, such as cardiovascular disease (CVD) or diabetes, are considered at greater risk to serious infection and complications.1 There has been a high prevalence of CVD in those dying from COVID-19 in Italy and China, two of the worst…

Read More

Here’s some scientific nomenclature to help kick-start your Monday! For centuries before the advent of coronavirus, many contagions, including the Bubonic Plague, syphilis, smallpox and tuberculosis, claimed the lives of hundreds of millions of people worldwide. Ironically, many of these contagions were awarded a ‘rainbow’ of names. Syphilis – a bacterial infection commonly spread by…

Read More

Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…

Read More